Dark day for FDA. Approving a drug on the basis of post-hoc analysis of a failed trial, in the context of a 2nd failed trial, a worrisome safety signal, and an exorbitant price. Promoting false hope for Alzheimer’s is not in the best interest of patients nytimes.com/2021/06/07/hea…

‼️ #CADTHSymp: Now Accepting Call for Abstracts Relevant topics: - Uncertainty in #HealthPolicy and #HealthCare delivery - Unconscious bias in health research - Real-world evidence #RWE - Drugs #RareDiseases ++ Submission Deadline: June 22 2021 cadth.info/3puTDpE #HTA

Announcing the release of the INAHTA Position Statement on Patient Involvement ! This statement reflects INAHTA members’ views on the role of patient involvement in #HTA. View full statement here: bit.ly/3cS5EjQ #patientinvolvement

INAHTA and HTAi have renewed their Memoranda of Understanding, continuing a long & valuable relationship. The MOU, originally signed in 2008, was renewed in 2021 ensuring that MOU activities are ready for the future of HTA. Thank you HTAi, for being a great MOU partner!

ISPOR is thinking about many things, states Nancy Berg, including: Effectively communicating the value of #HEOR. Supporting #payers & decision makers. Digital transformation of #healthcare. Aligning HEOR and #technology. And more! #ISPOREurope

Up at 5:00 AM to listen to the opening plenary of #ISPOREurope Looking forward to hearing from moderator Dr. Guido Rasi and the panelists.

Opening plenary at #ISPOREurope Dr. Jo De Cock from INAMI Belgium describing a multi-stakeholder, international payer led initiative called RWE4Decisions. A key point mentioned by Dr. De Cock is that Outcomes-based MEAs should contain a clear RWE generation plan. ISPOR

Plenary 1: Rui Santos Ivo of INFARMED, I. P. discusses an integrated approach and areas of action in scientific and regulatory advice including promoting timely access to medicines that introduce added value at a fair price, sustainable to NHS. #ISPOREurope #HTA

During the opening plenary at #ISPOREurope Dr. Hans-Georg Eichler stated that drugs with a small effect size and a small target population will have unavoidable uncertainty and that conventional HTA approaches will not be feasible. ISPOR

Hey, fellow ISPOR members! It’s time to vote for your next president! Here’s a little video message from me about this election & videos from each of our two brilliant candidates: @jasminepwu and Brian O'Rourke ⬇️ ispor.org/about/our-lead… The ballot is now open, so VOTE!!🗳️

Announcing the release of the INAHTA Position Statement on Disruptive Technologies! This statement reflects members’ views on the concept of disruptive technologies – a topic of significant interest amongst the INAHTA membership. View full statement here: bit.ly/3cS5EjQ

It’s the 71st annual CMHA Mental Health Week! Please read this important message from the CAF Surgeon General: canada.ca/en/department-… Also, keep your eyes on the @CFHSvcs account for content throughout the week. #CMHW2022 #GetReal #MentalHealth #WellBeing

Thank you to all of the participants of the 2022 ISPOR Health Technology Assessment Roundtable - Europe for an engaging and fruitful dialogue! Special thanks to the Chairs for their exceptional leadership and the speakers for their insightful presentations. #ISPOREurope #HTA

#ISPOREurope “Medical innovation only matters when it reaches the patient” says Emer Cooke from EU Medicines Agency

#ISPOREurope “Its the evidence stupid!” Great quote from Iga Lipska MD PhD MPH during the opening plenary of ISPOR Europe 2022.

Second plenary at #ISPOREurope is focused on real world use of patient-centred research, with a description of the Darwin EU initiative from the EU Medicines Agency Many questions arise with Darwin, including whether it will be used to support both regulatory and reimbursement decisions.

Atttending the Women in HEOR session at #ISPOREurope Very proud to wear my ribbon signifying me as a Cool Guy Ally to Women in HEOR.

gildehealthcare.com/news/general/g…

In the latest ISPORJournals Value & Outcomes Spotlight Brian O'Rourke & I talk about the 2022 ISPOR Payer Summit & report on key findings Big thanks to Carole Longson, Peter Neumann, Iga Lipska MD PhD MPH, & Alan Balch for their presentations #HTA #Payers #PBMs ispor.org/publications/j…

Very pleased to be representing ISPOR at the @ICHOM2023 conference in Barcelona. 650 delegates from 46 countries attending the conference to share and learn about the important work being done by ICHOM in developing core outcome sets.